<DOC>
	<DOC>NCT01594125</DOC>
	<brief_summary>The aim of the study is to investigate the safety, tolerability, efficacy and pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to curative surgery or loco regional therapy</brief_summary>
	<brief_title>Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criteria: 1. Histologically/cytologically confirmed hepatocellular carcinoma not amenable to curative surgery or locoregional therapy 2. Age 20 years or older 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1 4. ChildPugh score of 7 or less 5. Life expectancy more than 3 months 6. Time interval from last locoregional therapy more than 4 weeks 7. Written informed consent in accordance with good clinical practice (GCP) Exclusion criteria: 1. More than one line of prior systemic therapy for metastatic/unresectable hepatocellular carcinoma (HCC) 2. Fibrolamellar HCC 3. Uncontrolled or refractory ascites 4. Inadequate organ function 5. Variceal bleeding within 6 months or the presence of inappropriate varices 6. History of major thrombotic (except portal vein thrombosis) or clinically relevant major bleeding event in the past 6 months 7. Major surgery within 4 weeks 8. Known inherited predisposition to bleeding or thrombosis 9. Significant cardiovascular diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>